We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01020682
Recruitment Status : Unknown
Verified November 2009 by University Hospital, Grenoble.
Recruitment status was:  Recruiting
First Posted : November 25, 2009
Last Update Posted : November 25, 2009
Sponsor:
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by:
University Hospital, Grenoble

Brief Summary:
Apathy has been reported to occur after subthalamic nucleus stimulation (STN-DBS), a treatment of motor complications in advanced Parkinson's disease (PD). It is not known whether postoperative apathy is related to dopamine withdrawal or a side effect of STN DBS. The researchers investigated potential predictors of apathy, and the effect of dopamine agonist treatment.

Condition or disease
Apathy in Parkinson Disease

Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study
Study Start Date : January 2005
Primary Completion Date : February 2006
Estimated Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Parkinson's disease
Criteria

Inclusion Criteria:

  • Parkinson disease

Exclusion Criteria:

  • Mattis scale < 130
  • Beck scale > 20

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01020682


Contacts
Contact: Krack Paul, MD 0476765791 paul.krack@ujf-grenoble.fr

Locations
France
Hopital neurologique Recruiting
Lyon, France, 69000
Contact: Broussolle , MD         
Sponsors and Collaborators
University Hospital, Grenoble
Institut National de la Santé Et de la Recherche Médicale, France

Responsible Party: Délégation à la recherche clinique, CHU de grenoble
ClinicalTrials.gov Identifier: NCT01020682     History of Changes
Other Study ID Numbers: APATHIE
First Posted: November 25, 2009    Key Record Dates
Last Update Posted: November 25, 2009
Last Verified: November 2009

Keywords provided by University Hospital, Grenoble:
apathy
parkinson
agonist dopaminergic

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases